[Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
OBJECTIVE
To evaluate the safety and efficacy of strontium-89-chloride for management of bone metastases in patients without bone pain.


METHODS
Fifty-four patients without painful bone metastases were given a single intravenous dose (1.48-2.22 MBq/kg) of strontium-89-chloride, which was repeated once or twice at the interval between 3 and 6 months.


RESULTS
The total response rate was 74.0% in these, and the response rate was significantly lower in patients with focal size>2 cm than in those with focal size<or=2 cm (33.3% vs 66.6%, chi2=14.9, P<0.01). The side effects of strontium-89-chloride included mainly thrombocytopenia and neutropenia, mostly mild and reversible without interventions.


CONCLUSIONS
Strontium-89-chloride is effective and safe for treatment of nonpainful bone metastases.
Ouyang
Wei
W
Department of Nuclear Medicine, Zhujiang Hospital, South Medical University, Guangzhou 510282, China. oyw88@ tom.com
Liu
Jin-hua
JH
Liu
Wei-ying
WY
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000150:complications / Q000532:radiotherapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D011471:Prostatic Neoplasms / Q000473:pathology; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D016896:Treatment Outcome
D013326:Strontium Radioisotopes